Clinical

The AJMC^® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care^® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.

Latest News

Image depicting the global population | Image Credit: flashmovie - stock.adobe.com

Global Trends in Ovarian Cancer Incidence Highlight Regional, Histological Variations

By Brooke McCormick

January 7th 2025

Between 1988 and 2017, there were significant global variations and trends in ovarian cancer incidence and its subtypes, influenced by genetic, reproductive, and socioeconomic factors.

Studies presented at ASH 2024 added to the understanding of real-world treatment and outcomes for patients with pediatric AML. | Image credit: LASZLO - stock.adobe.com

Studies Examine Real-World Pediatric AML Treatment and Outcomes

By Kimberly Rath, PharmD

January 7th 2025

MRD ahead of allo-HSCT showed prognostic value in patients with AML and MDS. | Image credit: keetazalay - stock.adobe.com

MRD Status Prior to Allo-HSCT Shows Strong Prognostic Value in AML, MDS

By Kimberly Rath, PharmD

January 6th 2025

Patients with MS had higher odds of filling prescriptions for anticonvulsants and higher odds of filling gabapentinoids and gabapentinoids without other anticonvulsants in the years leading up to onset of MS. | Image credit: Vitalii Vodolazskyi - stock.adobe.com

Pain May Be Indicator of MS Prior to Disease Onset: Study

By AJMC Contributor

January 6th 2025

Doctor holding a card that says "eosinophilic esophagitis" | Image Credit: Yurii Kibalnik - stock.adobe.com

Male Patients With Eosinophilic Esophagitis Face Higher Complication Rates

By Brooke McCormick

January 6th 2025

More News

Managing Discrepancies in NCCN and Payer Guidelines in Multiple Myeloma

Managing Discrepancies in NCCN and Payer Guidelines in Multiple Myeloma

Watch

Patient Cost Implications in Multiple Myeloma Treatment

Patient Cost Implications in Multiple Myeloma Treatment

Watch

$Treatment Options in Relapsed/Refractory Multiple Myeloma$

Treatment Options in Relapsed/Refractory Multiple Myeloma

Watch

Reimbursement of Subcutaneous Versus IV Dosing in Multiple Myeloma

Reimbursement of Subcutaneous Versus IV Dosing in Multiple Myeloma

Watch

OCM Ensures Better Outcomes and Automatic Cost Savings in Multiple Myeloma

OCM Ensures Better Outcomes and Automatic Cost Savings in Multiple Myeloma

Watch

The Impact of OCM in the Treatment of Multiple Myeloma

The Impact of OCM in the Treatment of Multiple Myeloma

Watch

Entering a 4-Drug Regimen for Multiple Myeloma Treatment

Entering a 4-Drug Regimen for Multiple Myeloma Treatment

Watch

MAIA Trial: Transplant-Ineligible Patients With MM

MAIA Trial: Transplant-Ineligible Patients With MM

Watch

Using MRD Negativity to Stop Maintenance Therapy in MM

Using MRD Negativity to Stop Maintenance Therapy in MM

Watch

Long-term Data on Improving OS for Patients With MM

Long-term Data on Improving OS for Patients With MM

Watch

Payer Perspective: Transplant and Toxicities in MM Therapy

Payer Perspective: Transplant and Toxicities in MM Therapy

Watch

FORTE Trial: Transplant in Patients with Multiple Myeloma

FORTE Trial: Transplant in Patients with Multiple Myeloma

Watch

Impact of Maintenance Therapy in Multiple Myeloma

Impact of Maintenance Therapy in Multiple Myeloma

Watch

Strategy for Up-front Therapy of Multiple Myeloma

Strategy for Up-front Therapy of Multiple Myeloma

Watch

Backbone Therapy in Newly Diagnosed Multiple Myeloma

Backbone Therapy in Newly Diagnosed Multiple Myeloma

Watch

How Real-World Data Can Address Problems in MM

How Real-World Data Can Address Problems in MM

Watch

$Dosing Strategies in Relapsed-Refractory MM$

Dosing Strategies in Relapsed-Refractory MM

Watch

$Initiating Treatment in Relapsed-Refractory MM$

Initiating Treatment in Relapsed-Refractory MM

Watch

What Is the Cost of Recurrence in Multiple Myeloma?

What Is the Cost of Recurrence in Multiple Myeloma?

Watch

Daratumumab in the Treatment Landscape for MM

Daratumumab in the Treatment Landscape for MM

Watch

Clinical Significance of MRD Testing in MM

Clinical Significance of MRD Testing in MM

Watch

Practical Implications of the MAIA Study for MM

Practical Implications of the MAIA Study for MM

Watch

Considerations for Transplant-Ineligible Patients

Considerations for Transplant-Ineligible Patients

Watch

NCCN Guidelines for Newly Diagnosed MM

NCCN Guidelines for Newly Diagnosed MM

Watch

Achieving the Best Outcomes for Patients With MM

Achieving the Best Outcomes for Patients With MM

Watch

Cost Considerations of Multidrug Regimens in MM

Cost Considerations of Multidrug Regimens in MM

Watch

Factoring Age Into Frontline Therapy for MM

Factoring Age Into Frontline Therapy for MM

Watch

Individualizing Therapy for Multiple Myeloma Patients

Individualizing Therapy for Multiple Myeloma Patients

Watch

June Halper Outlines the Biggest Management Challenges in Multiple Sclerosis

June Halper Outlines the Biggest Management Challenges in Multiple Sclerosis

The biggest clinical challenges that we have in treating multiple sclerosis are 2-fold, explained June Halper, MSN, APN-C, MSCN, FAAN, chief executive officer, Consortium of Multiple Sclerosis Centers.

Watch

Evaluating Use of Bone-Modifying Agents to Treat Skeletal-Related Events in Cancer

Evaluating Use of Bone-Modifying Agents to Treat Skeletal-Related Events in Cancer

Laura Joszt, MA

Skeletal-related events are frequent complications in patients with cancers. Two abstracts analyzed the use of bone-modifying agents in patients with newly diagnosed multiple myeloma and breast cancer.

Read More

...

174 175 176 177 178 179 180 181 182

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions